Biogen Buys Biotech Firm HI-Bio to Boost Its Immunology Port

Biogen Buys Biotech Firm HI-Bio to Boost Its Immunology Portfolio

Biogen has agreed to pay at least $1.15 billion for biotech firm Human Immunology Biosciences as it moves to increase its immunology portfolio.

Related Keywords

Priya Singhal , Head Of Development At Biogen , Human Immunology Biosciences ,

© 2024 Vimarsana